GEHC: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-06-01
Other years: 2026 vs 2025
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
18
Removed
13
Modified
21
Unchanged
🔴 No Match in Current Filing Our business dealings involve third-party partners in various markets, and the actions or inactions of these third parties could adversely affect our business. 🔒
🔴 No Match in Current Filing We rely on third parties to help perform logistics, transportation, shipping, warehousing, and services functions on our behalf, and disruptions at these third-party providers could adversely affect our business. 🔒
🔴 No Match in Current Filing Changes in accounting standards and subjective assumptions, estimates, and judgments by management related to complex accounting matters could significantly affect our financial results and/or financial condition. 🔒
🔴 No Match in Current Filing Our tax burden could increase as a result of ongoing or future tax audits. 🔒
🔴 No Match in Current Filing Our ability to use deferred tax assets may be subject to limitation. 🔒
🔴 No Match in Current Filing Our business operations are subject to extensive laws and regulations, and any changes thereto or violations thereof could have a material adverse effect on our business. 🔒
🔴 No Match in Current Filing The U.S. FDA and other regulatory agencies actively enforce the laws and regulations governing the development, approval, and clearance and commercialization of medical devices and pharmaceutical products. 🔒
🔴 No Match in Current Filing In the United States, the FDA actively enforces laws and regulations governing the manufacture of medical devices and pharmaceutical products, and failure to comply with applicable laws and regulations could adversely affect our business. 🔒
🔴 No Match in Current Filing Compliance with laws and regulations applicable to the manufacture and distribution of our products outside the United States may be costly, and failure to comply may result in significant penalties. 🔒
🔴 No Match in Current Filing The misuse or off-label use of our products may harm our reputation or, if we are deemed to have engaged in the promotion of these uses, result in costly investigations, fines, or sanctions by regulatory bodies. 🔒
🔴 No Match in Current Filing Demand for some of our products depends on capital spending policies of our customers and on government funding policies. 🔒
🔴 No Match in Current Filing Consolidation in the U.S. healthcare industry and other changes to the U.S. healthcare environment may adversely affect our business. 🔒
🔴 No Match in Current Filing We agreed to numerous restrictions to preserve the non-recognition tax treatment of our Spin-Off from GE, which may reduce our strategic and operating flexibility. 🔒
🔴 No Match in Current Filing We have limited operating history as an independent, publicly traded company, and our pre-Spin-Off historical combined financial information is not necessarily representative of the results we may have achieved as an independent, publicly traded company and may not be a reliable indicator of our post-Spin-Off results. 🔒
🔴 No Match in Current Filing We may not be able to access the capital markets on terms that are favorable to us, or at all. 🔒
🔴 No Match in Current Filing A lowering or withdrawal of the ratings, outlook, or watch assigned to our debt by rating agencies may increase our future borrowing costs, reduce our access to capital, and adversely impact our financial performance. 🔒
🔴 No Match in Current Filing Substantial sales of our common stock, including the disposition by GE of shares of our common stock that it retained after the Spin-Off, could cause our stock price to decline or be volatile. 🔒
🔴 No Match in Current Filing Holders of our common stock may be diluted due to future equity issuances. 🔒
🟡 Modified We are subject to laws and regulations governing government contracts and public procurement, as well as policies of our customers on capital spending and government reimbursement and funding in many jurisdictions, as to which the failure to comply with or changes to such laws, regulations, or policies could adversely affect our business. 🔒
🟡 Modified Any interruption in the operations of our facilities, or our suppliers’, customers’, or third-party providers’ facilities, may impair our ability to deliver products or provide services. 🔒
🟡 Modified Our inability to manage our supply chain or obtain supplies of components or raw materials has restricted, and could continue to restrict, the manufacturing of products, cause delays in delivery, or significantly increase our costs, and our use of third parties in various markets and their actions or inactions could affect our business. 🔒
🟡 Modified Global geopolitical and economic instability, as well as continuing uncertainties and challenging conditions in regional economies, could adversely affect our business. 🔒
🟡 Modified We operate in highly competitive markets, competition may increase in the future, and our industry may be disrupted, requiring us to lower prices or resulting in a loss of market share. 🔒
🟡 Modified Complying with our requirements under our debt instruments could adversely affect our business, results of operations, cash flows, and financial condition. 🔒
🟡 Modified Increasing attention to ESG matters, including EH&S matters, may impose additional costs on our business and expose us to new risks. 🔒
🟡 Modified SUMMARY OF RISK FACTORS. 🔒
🟡 Modified Changes in applicable tax laws and regulations, as well as adverse outcomes of ongoing and future tax audits, could adversely affect our business and our ability to use deferred tax assets. 🔒
🟡 Modified Changes in foreign currency exchange rates, equity prices, and interest rates, and unfavorable changes in economic conditions or uncertainties that affect the capital markets could adversely affect our financial performance. 🔒
🟡 Modified We are subject to anti-kickback and false claims laws (including as these laws relate to off-label promotion of products) and failure to comply with these laws could adversely affect our business, including via sanctions and conditions on business activity. 🔒
🟡 Modified We are subject to stringent privacy laws and information security regulations. 🔒
🟡 Modified The U.S. FDA and equivalent global agencies tightly regulate and actively enforce the laws and regulations governing the development, authorization, and commercialization of medical devices and pharmaceutical products. 🔒
31 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →